FINASTERIDE Drug Patent Profile
✉ Email this page to a colleague
When do Finasteride patents expire, and what generic alternatives are available?
Finasteride is a drug marketed by Accord Hlthcare, Actavis Totowa, Actavis Totowa Teva, Alkem Labs Ltd, Aurobindo Pharma, Aurobindo Pharma Ltd, Cipla, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Gedeon Richter Usa, Hetero Labs Ltd Iii, Ivax Sub Teva Pharms, Mylan, Sun Pharm, Teva, and Zydus Pharms Usa Inc. and is included in twenty-two NDAs.
The generic ingredient in FINASTERIDE is finasteride. There are fourteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the finasteride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Finasteride
A generic version of FINASTERIDE was approved as finasteride by DR REDDYS LABS INC on July 28th, 2006.
Summary for FINASTERIDE
Recent Clinical Trials for FINASTERIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Follicle Pharma Ltd | Phase 1 |
Vanderbilt University Medical Center | Phase 2 |
Mohammed Abd El Mawgoud Amer | N/A |
Pharmacology for FINASTERIDE
Drug Class | 5-alpha Reductase Inhibitor |
Mechanism of Action | 5-alpha Reductase Inhibitors |